Cabaletta Bio (CABA) Competitors $1.55 +0.05 (+3.33%) Closing price 04:00 PM EasternExtended Trading$1.53 -0.02 (-1.29%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CABA vs. ALDX, AVIR, GLUE, ESPR, CRVS, OCGN, SCPH, ALT, FHTX, and TLSAShould you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Aldeyra Therapeutics (ALDX), Atea Pharmaceuticals (AVIR), Monte Rosa Therapeutics (GLUE), Esperion Therapeutics (ESPR), Corvus Pharmaceuticals (CRVS), Ocugen (OCGN), scPharmaceuticals (SCPH), Altimmune (ALT), Foghorn Therapeutics (FHTX), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry. Cabaletta Bio vs. Its Competitors Aldeyra Therapeutics Atea Pharmaceuticals Monte Rosa Therapeutics Esperion Therapeutics Corvus Pharmaceuticals Ocugen scPharmaceuticals Altimmune Foghorn Therapeutics Tiziana Life Sciences Cabaletta Bio (NASDAQ:CABA) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations. Which has more volatility & risk, CABA or ALDX? Cabaletta Bio has a beta of 2.74, meaning that its share price is 174% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Does the media refer more to CABA or ALDX? In the previous week, Cabaletta Bio and Cabaletta Bio both had 1 articles in the media. Cabaletta Bio's average media sentiment score of 0.00 equaled Aldeyra Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aldeyra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is CABA or ALDX more profitable? Aldeyra Therapeutics' return on equity of -72.58% beat Cabaletta Bio's return on equity.Company Net Margins Return on Equity Return on Assets Cabaletta BioN/A -78.29% -65.68% Aldeyra Therapeutics N/A -72.58%-52.32% Do institutionals and insiders believe in CABA or ALDX? 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 11.3% of Cabaletta Bio shares are owned by company insiders. Comparatively, 8.5% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher earnings & valuation, CABA or ALDX? Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCabaletta BioN/AN/A-$115.86M-$2.54-0.61Aldeyra TherapeuticsN/AN/A-$55.85M-$0.97-5.32 Do analysts recommend CABA or ALDX? Cabaletta Bio currently has a consensus target price of $14.43, indicating a potential upside of 830.88%. Aldeyra Therapeutics has a consensus target price of $9.50, indicating a potential upside of 84.11%. Given Cabaletta Bio's higher possible upside, equities analysts clearly believe Cabaletta Bio is more favorable than Aldeyra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Aldeyra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCabaletta Bio beats Aldeyra Therapeutics on 6 of the 11 factors compared between the two stocks. Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CABA vs. The Competition Export to ExcelMetricCabaletta BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$76.11M$3.07B$5.59B$9.54BDividend YieldN/A2.41%4.73%4.13%P/E Ratio-0.6117.5328.8823.86Price / SalesN/A314.01445.9598.86Price / CashN/A42.6035.6858.35Price / Book0.507.828.165.60Net Income-$115.86M-$54.52M$3.25B$265.26M7 Day Performance-1.27%2.07%0.45%-1.00%1 Month Performance-3.49%17.29%8.27%6.09%1 Year Performance-76.12%14.95%30.29%23.81% Cabaletta Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CABACabaletta Bio1.7986 of 5 stars$1.55+3.3%$14.43+830.9%-77.6%$76.11MN/A-0.6150News CoveragePositive NewsUpcoming EarningsALDXAldeyra Therapeutics1.4309 of 5 stars$5.08+5.6%$9.50+87.0%+44.5%$304.29MN/A-5.2410Upcoming EarningsAVIRAtea Pharmaceuticals1.5634 of 5 stars$3.53+1.7%$6.00+70.0%+2.3%$302.09MN/A-2.1470Upcoming EarningsGLUEMonte Rosa Therapeutics1.2665 of 5 stars$4.88+1.9%$15.33+214.2%+21.7%$300.17M$75.62M61.0190ESPREsperion Therapeutics4.0551 of 5 stars$1.49+6.4%$7.00+369.8%-27.7%$295.32M$332.31M-1.86200News CoverageEarnings ReportGap UpCRVSCorvus Pharmaceuticals2.4241 of 5 stars$4.31+5.1%$15.00+248.0%+44.6%$293.81MN/A-4.4030News CoverageUpcoming EarningsOCGNOcugen1.62 of 5 stars$1.00+0.6%$6.00+500.0%-18.4%$292.03M$4.75M-5.0080News CoverageEarnings ReportAnalyst ForecastSCPHscPharmaceuticals3.5307 of 5 stars$5.52+6.8%$14.00+153.6%+22.1%$291.40M$36.33M-2.8930News CoverageUpcoming EarningsALTAltimmune1.8935 of 5 stars$3.58-0.8%$18.20+408.4%-40.3%$290.36M$20K-2.8450Upcoming EarningsFHTXFoghorn Therapeutics3.2149 of 5 stars$5.14+3.0%$12.13+135.9%-16.0%$286.51M$23.50M-3.78120News CoverageEarnings ReportUpcoming EarningsTLSATiziana Life Sciences0.874 of 5 stars$2.45+2.9%N/A+142.7%$286.28MN/A0.008Positive News Related Companies and Tools Related Companies ALDX Competitors AVIR Competitors GLUE Competitors ESPR Competitors CRVS Competitors OCGN Competitors SCPH Competitors ALT Competitors FHTX Competitors TLSA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CABA) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CABA Stock Alerts